Page 1 | Search Results | Blood | American Society of Hematology

1-19 of 19

Sort by

Sort Order Select

Journal Articles

Dual BCL-2/BCL-XL Inhibitor Pelcitoclax (APG-1252) Overcomes Intrinsic and Acquired Resistance to Venetoclax in Multiple Myeloma Cells

Leona Yamamoto, Sanika Derebail, Anil Aktas-Samur, Teru Hideshima, Zuzana Chyra, Chandraditya Chakraborty, Yao Yao, Doriana Gramegna, Eugenio Morelli, Mehmet K. Samur, Jing Deng, Yifan Zhai, Annamaria Gulla, Mariateresa Fulciniti, Kenneth C. Anderson, Nikhil C. Munshi

Blood (2021) 138 (Supplement 1): 2655.

https://doi.org/10.1182/blood-2021-149530

Published: 2021

Journal Articles

Successful prenatal therapy for anti-CD36-mediated severe FNAIT by deglycosylated antibodies in a novel murine model

Xiuzhang Xu, Dawei Chen, Xin Ye, Wenjie Xia, Yaori Xu, Yangkai Chen, Yuan Shao, Jing Deng, Haoqiang Ding, Jing Liu, Jiali Wang, Heyu Ni, Yongshui Fu, Sentot Santoso

Blood (2021) 138 (18): 1757–1767.

https://doi.org/10.1182/blood.2021011131

Published: 2021

Includes: Supplemental data

Journal Articles

Targeting 1q21 Amplification with APG2575 and Lenalidomide to Sensitize BCL-2 Inhibition with the Decrease of MCL-1 Protein in High Risk MM Models

Yan Xie, MD, Chengcheng FU, MD PhD, Lingzhi Yan, MD PhD, Song Jin, MD, Jingjing Shang, MD, Xiaolan Shi, MD PhD, Jinlan Pan, MD, Yan Yin, MS, Tingting Mao, MS, Jing Deng, PhD, Douglas D. Fang, MD PhD, Dajun Yang, MD PhD, Yifan Zhai, MD PhD, Shuang Yan, MD, Yingying Zhai, MD, Ying Yao, MD, Panfeng Wang, MD, Jing Wang, MD, Depei Wu, MDPhD

Blood (2020) 136 (Supplement 1): 46–47.

https://doi.org/10.1182/blood-2020-139195

Published: 2020

Journal Articles

A Novel BCL-2/BCL-Xl Dual Inhibitor Overcomes Ibrutinib-Resistance Conferred By the Upregulation of Integrin Pathway and BCL-Xl

Jing Deng, PhD, Tingting Mao, MS, Xiaojing Huang, PhD, Li Rui, Guangfeng Wang, PhD, Douglas D. Fang, MD PhD, Dajun Yang, MD PhD, Yifan Zhai, MD PhD

Blood (2019) 134 (Supplement_1): 2573.

https://doi.org/10.1182/blood-2019-128708

Published: 2019

Journal Articles

Probing Distinct Oncogene Addiction By Novel BCL-2 Inhibitors

Jing Deng, PhD, Yan Yin, MS, Tingting Mao, MS, Guoqin Zhai, MS, Dongmei Yang, MS, Douglas Fang, MD PhD, Shaomeng Wang, PhD, Yifan Zhai, MD PhD, Dajun Yang, MD PhD

Blood (2018) 132 (Supplement 1): 2616.

https://doi.org/10.1182/blood-2018-99-119816

Published: 2018

Journal Articles

Dynamic BH3 Profiling to Assess the Effects of Novel Agents on Anti-Apoptotic Protein Dependence of CLL Cells

Rebecca Valentin, MD, Jing Deng, PhD, Elisa Ten Hacken, PhD, Timothy Z. Lehmberg, BA, Silvia Buonamici, PhD, Donna S. Neuberg, ScD, Catherine J. Wu, MD, Anthony Letai, MD PhD, Matthew S. Davids, MD MMSc

Blood (2017) 130 (Supplement 1): 4289.

https://doi.org/10.1182/blood.V130.Suppl_1.4289.4289

Published: 2017

Journal Articles

Dynamic BH3 Profiling Reveals Novel Therapeutic Strategies for the Treatment of Double-Hit Lymphoma

Jennifer Crombie, MD, Chen Lossos, BS, Kristopher Sarosiek, PhD, Amanda L Christie, BS, Cameron Fraser, BS, Shruti Bhatt, PhD, Jing Deng, PhD, Matthew S. Davids, MD, David M. Weinstock, MD, Anthony Letai, MD PhD

Blood (2017) 130 (Supplement 1): 2764.

https://doi.org/10.1182/blood.V130.Suppl_1.2764.2764

Published: 2017

Journal Articles

Splicing Modulation Perturbs Key Survival Pathways and Sensitizes Chronic Lymphocytic Leukemia to Venetoclax Treatment

Blood (2017) 130 (Supplement 1): 264.

https://doi.org/10.1182/blood.V130.Suppl_1.264.264

Published: 2017

Journal Articles

Acalabrutinib Increases Mitochondrial Priming and Enhances Venetoclax Sensitivity in CLL Cells

Jing Deng, PhD, Elif Isik, MD, Stacey M. Fernandes, MS, Jennifer R. Brown, Anthony Letai, MD PhD, Matthew S. Davids

Blood (2016) 128 (22): 4346.

https://doi.org/10.1182/blood.V128.22.4346.4346

Published: 2016

Journal Articles

The BCL2 selective inhibitor venetoclax induces rapid onset apoptosis of CLL cells in patients via a TP53-independent mechanism

Mary Ann Anderson, Jing Deng, John F. Seymour, Constantine Tam, Su Young Kim, Joshua Fein, Lijian Yu, Jennifer R. Brown, David Westerman, Eric G. Si, Ian J. Majewski, David Segal, Sari L. Heitner Enschede, David C. S. Huang, Matthew S. Davids, Anthony Letai, Andrew W. Roberts

Blood (2016) 127 (25): 3215–3224.

https://doi.org/10.1182/blood-2016-01-688796

Published: 2016

Includes: Supplemental data

Journal Articles

Ibrutinib Therapy Increases BCL-2 Dependence and Enhances Sensitivity to Venetoclax in CLL

Jing Deng, Elif Isik, Stacey M. Fernandes, Jennifer R. Brown, MD PhD, Anthony Letai, MD PhD, Matthew S. Davids, MD

Blood (2015) 126 (23): 490.

https://doi.org/10.1182/blood.V126.23.490.490

Published: 2015

Journal Articles

Overuse of DVT Prophylaxis in Medical Inpatients

Jing Deng, MD, Lisa Thomas, MD, Huijing Li, MD, Elvin Varughesekutty, MD, Qi Shi, MD, Meenakshi Sambharia, MD, Kevin Musto, MD, Gaurav Petal, MD, Erin Gordon, MD, Sudeep Ruparella, MD, Rajiv Bansal, MD

Blood (2015) 126 (23): 5563.

https://doi.org/10.1182/blood.V126.23.5563.5563

Published: 2015

Journal Articles

Mitochondrial Apoptotic Priming Is Associated with Clinical Response to the Bcl-2 Antagonist ABT-199 in Chronic Lymphocytic Leukemia

Matthew S. Davids, MD, Jing Deng, PhD, Jeremy Ryan, SM, Stacey M. Fernandes, Jennifer R. Brown, Anthony G. Letai, MD PhD

Blood (2014) 124 (21): 1940.

https://doi.org/10.1182/blood.V124.21.1940.1940

Published: 2014

Journal Articles

Therapeutic Targeting of the Bcl2 Family

Anthony Letai, MD, PhD, Matthew S. Davids, MD, Triona Ni Chonghaile, PhD, Jing Deng, PhD, Luv Patel, B.S.

Blood (2013) 122 (21): SCI-42.

https://doi.org/10.1182/blood.V122.21.SCI-42.SCI-42

Published: 2013

Journal Articles

Decreased mitochondrial apoptotic priming underlies stroma-mediated treatment resistance in chronic lymphocytic leukemia

Matthew S. Davids, Jing Deng, Adrian Wiestner, Brian J. Lannutti, Lili Wang, Catherine J. Wu, Wyndham H. Wilson, Jennifer R. Brown, Anthony Letai

Blood (2012) 120 (17): 3501–3509.

https://doi.org/10.1182/blood-2012-02-414060

Published: 2012

Includes: Supplemental data

Journal Articles

Functional PU.1 in macrophages has a pivotal role in NF-κB activation and neutrophilic lung inflammation during endotoxemia

Manjula Karpurapu, Xuerong Wang, Jing Deng, Hyesuk Park, Lei Xiao, Ruxana T. Sadikot, Randall S. Frey, Ulrich A. Maus, Gye Young Park, Edward W. Scott, John W. Christman

Blood (2011) 118 (19): 5255–5266.

https://doi.org/10.1182/blood-2011-03-341123

Published: 2011

Includes: Supplemental data

Journal Articles

Acquired resistance to ABT-737 in lymphoma cells that up-regulate MCL-1 and BFL-1

Derek Yecies, Nicole E. Carlson, Jing Deng, Anthony Letai

Blood (2010) 115 (16): 3304–3313.

https://doi.org/10.1182/blood-2009-07-233304

Published: 2010

Journal Articles

Detecting Apoptotic Blocks and Sensitvity to ABT-737 and Conventional Chemotherapy Via BH3 Profiling.

Anthony Letai, MD, PhD, Margaret Shipp, MD, Paola dal Cin, MD, Kunihiko Takeyama, PhD, Jing Deng, PhD

Blood (2007) 110 (11): 4523.

https://doi.org/10.1182/blood.V110.11.4523.4523

Published: 2007

Journal Articles

Experimental Study on Prevention of GVHD by Selective Elimination of Alloreactive Donor Lymphocytes Prior to Stem Cell Transplantation.

Bao-An Chen, MD, PhD, Wei-Min Dong, MD, Jia-Hua Ding, MD, Xiao-Jing Deng, MD, Gang Zhao, MD, Chong Gao, MD, Yun-Yu Sun, MD, Jun Wang, MD, Jian Cheng, MD, Ning-Na Chen, MD, Fei Fei, MD

Blood (2006) 108 (11): 5161.

https://doi.org/10.1182/blood.V108.11.5161.5161

Published: 2006

NARROW

Dual BCL-2/BCL-XL Inhibitor Pelcitoclax (APG-1252) Overcomes Intrinsic and Acquired Resistance to Venetoclax in Multiple Myeloma Cells

Successful prenatal therapy for anti-CD36-mediated severe FNAIT by deglycosylated antibodies in a novel murine model

Targeting 1q21 Amplification with APG2575 and Lenalidomide to Sensitize BCL-2 Inhibition with the Decrease of MCL-1 Protein in High Risk MM Models

A Novel BCL-2/BCL-Xl Dual Inhibitor Overcomes Ibrutinib-Resistance Conferred By the Upregulation of Integrin Pathway and BCL-Xl

Probing Distinct Oncogene Addiction By Novel BCL-2 Inhibitors

Dynamic BH3 Profiling to Assess the Effects of Novel Agents on Anti-Apoptotic Protein Dependence of CLL Cells

Dynamic BH3 Profiling Reveals Novel Therapeutic Strategies for the Treatment of Double-Hit Lymphoma

Splicing Modulation Perturbs Key Survival Pathways and Sensitizes Chronic Lymphocytic Leukemia to Venetoclax Treatment

Acalabrutinib Increases Mitochondrial Priming and Enhances Venetoclax Sensitivity in CLL Cells

The BCL2 selective inhibitor venetoclax induces rapid onset apoptosis of CLL cells in patients via a TP53-independent mechanism

Ibrutinib Therapy Increases BCL-2 Dependence and Enhances Sensitivity to Venetoclax in CLL

Overuse of DVT Prophylaxis in Medical Inpatients

Mitochondrial Apoptotic Priming Is Associated with Clinical Response to the Bcl-2 Antagonist ABT-199 in Chronic Lymphocytic Leukemia

Therapeutic Targeting of the Bcl2 Family

Decreased mitochondrial apoptotic priming underlies stroma-mediated treatment resistance in chronic lymphocytic leukemia

Functional PU.1 in macrophages has a pivotal role in NF-κB activation and neutrophilic lung inflammation during endotoxemia

Acquired resistance to ABT-737 in lymphoma cells that up-regulate MCL-1 and BFL-1

Detecting Apoptotic Blocks and Sensitvity to ABT-737 and Conventional Chemotherapy Via BH3 Profiling.

Experimental Study on Prevention of GVHD by Selective Elimination of Alloreactive Donor Lymphocytes Prior to Stem Cell Transplantation.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only